A detailed history of Gamma Investing LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Gamma Investing LLC holds 1,178 shares of RCUS stock, worth $18,494. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,178
Previous 1,166 1.03%
Holding current value
$18,494
Previous $17.8 Million 1.43%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

BUY
$13.69 - $18.01 $164 - $216
12 Added 1.03%
1,178 $18 Million
Q2 2024

Jul 02, 2024

SELL
$14.59 - $18.48 $18,397 - $23,303
-1,261 Reduced 51.96%
1,166 $17.8 Million
Q1 2024

Apr 05, 2024

BUY
$14.83 - $20.18 $12,249 - $16,668
826 Added 51.59%
2,427 $45.8 Million
Q4 2023

Feb 01, 2024

BUY
$13.43 - $19.63 $21,501 - $31,427
1,601 New
1,601 $24.2 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.13B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Gamma Investing LLC Portfolio

Follow Gamma Investing LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gamma Investing LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gamma Investing LLC with notifications on news.